TransCode Therapeutics surges on positive trial data for cancer drug

Transcode Therapeutics

26/10/2022 12:55

**  Shares of biotech co TransCode Therapeutics Inc  RNAZ.O 
jump 26.9% to $1.4 premarket
    ** Co reports positive pre-clinical data for its lead
TTX-MC138 in treating Pancreatic adenocarcinoma, a type of
pancreatic cancer that starts in the ducts of the pancreas
 urn:newsml:reuters.com:*:nGNXNPpxV
    ** The study tested the drug on mice who were treated once
weekly for 10 weeks with TTX-MC138; 40% of the animals showed
complete regression of disease and long-term survival without
recurrence - co
    ** RNAZ says additional studies to better define the optimal
dose and therapeutic window in pancreatic cancer are ongoing
    ** The emerging RNA oncology co expects to file application
for human trial of the drug with U.S. FDA this year in treating
cancer patients with advanced solid tumors
    ** RNAZ down 57.5% YTD, as of last close
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))